Evidence suggests that interleukin-10（IL-10） deficiency exacerbates inflammation and worsens the outcome of brain ischemia. In view of the critical role of the single nucleotide polymorphic sites-1082（A/G） and-819...Evidence suggests that interleukin-10（IL-10） deficiency exacerbates inflammation and worsens the outcome of brain ischemia. In view of the critical role of the single nucleotide polymorphic sites-1082（A/G） and-819（C/T） in the promoter region of the IL-10 gene, we hypothesized that they are associated with cerebral infarction morbidity in the Chinese Han population. We genotyped these allelic gene polymorphisms by amplification refractory mutation system-polymerase chain reaction methods in 181 patients with cerebral infarction（cerebral infarction group） and 115 healthy subjects（control group）. We identified significant differences in genotype distribution and allele frequency of the IL-10-1082 A/G allele between cerebral infarction and control groups（χ2 = 6.643, P = 0.010）. The IL-10-1082 A allele frequency was significantly higher in the cerebral infarction group（92.3%） than in the control group（86.1%）（P = 0.015）. Moreover, cerebral infarction risk of the AA genotype was 2-fold higher than with the AG genotype（OR = 2.031, 95%CI： 1.134-3.637）. In addition, AA genotype together with hypertension was the independent risk factor of cerebral infarction（OR = 2.073, 95%CI： 1.278-3.364）. No statistical difference in genotype distribution or allele frequency of IL-10-819 C/T was found between cerebral infarction and control groups（P 〉 0.05）. These findings suggest that the IL-10-1082 A/G gene polymorphism is involved in cerebral infarction, and increased A allele frequency is closely associated with occurrence of cerebral infarction.展开更多
目的:探讨激素联合孟鲁司特对支气管哮喘患儿外周血中调节性T细胞表达的影响及临床疗效。方法:将80例支气管哮喘患儿随机分为常规治疗组和孟鲁司特组各40例。常规治疗组仅给予布地奈德混悬液0.5 mg/2 m L雾化吸入治疗,每次1吸,每天1次,...目的:探讨激素联合孟鲁司特对支气管哮喘患儿外周血中调节性T细胞表达的影响及临床疗效。方法:将80例支气管哮喘患儿随机分为常规治疗组和孟鲁司特组各40例。常规治疗组仅给予布地奈德混悬液0.5 mg/2 m L雾化吸入治疗,每次1吸,每天1次,连续治疗3个月。孟鲁司特组在此基础上加用孟鲁司特钠咀嚼片5 mg,1次/天,睡前口服,连用3个月。采用流式细胞术检测两组患儿治疗前后外周血中CD4+CD25+Foxp3+Treg表达水平,ELISA检测患儿血清中TGF-β1、白介素-10(IL-10)的蛋白表达水平,并进行日、夜间症状评分。结果:两组患儿治疗后日、夜间症状评分均较治疗前显著下降(P<0.05),但孟鲁司特组较常规治疗组下降更为明显(P<0.05);与治疗前相比,治疗3个月后孟鲁司特组和常规治疗组患儿Treg百分率、血清中TGF-β1和IL-10水平均有明显升高(P<0.05),且孟鲁司特组上述指标的升高水平较常规治疗组更显著(P<0.05)。结论:孟鲁司特能有效抑制哮喘的机制,有可能是通过上调哮喘患儿Treg比例,进而分泌表达TGF-β1、IL-10,抑制哮喘中的炎症反应,并显著改善哮喘患儿日、夜间症状评分。展开更多
基金supported by the National Natural Science Foundation of ChinaNo.81171867+1 种基金a grant from the Key Research Program of Fujian Department of Science and Technology of ChinaNo.2011Y0027
文摘Evidence suggests that interleukin-10（IL-10） deficiency exacerbates inflammation and worsens the outcome of brain ischemia. In view of the critical role of the single nucleotide polymorphic sites-1082（A/G） and-819（C/T） in the promoter region of the IL-10 gene, we hypothesized that they are associated with cerebral infarction morbidity in the Chinese Han population. We genotyped these allelic gene polymorphisms by amplification refractory mutation system-polymerase chain reaction methods in 181 patients with cerebral infarction（cerebral infarction group） and 115 healthy subjects（control group）. We identified significant differences in genotype distribution and allele frequency of the IL-10-1082 A/G allele between cerebral infarction and control groups（χ2 = 6.643, P = 0.010）. The IL-10-1082 A allele frequency was significantly higher in the cerebral infarction group（92.3%） than in the control group（86.1%）（P = 0.015）. Moreover, cerebral infarction risk of the AA genotype was 2-fold higher than with the AG genotype（OR = 2.031, 95%CI： 1.134-3.637）. In addition, AA genotype together with hypertension was the independent risk factor of cerebral infarction（OR = 2.073, 95%CI： 1.278-3.364）. No statistical difference in genotype distribution or allele frequency of IL-10-819 C/T was found between cerebral infarction and control groups（P 〉 0.05）. These findings suggest that the IL-10-1082 A/G gene polymorphism is involved in cerebral infarction, and increased A allele frequency is closely associated with occurrence of cerebral infarction.
文摘目的:探讨激素联合孟鲁司特对支气管哮喘患儿外周血中调节性T细胞表达的影响及临床疗效。方法:将80例支气管哮喘患儿随机分为常规治疗组和孟鲁司特组各40例。常规治疗组仅给予布地奈德混悬液0.5 mg/2 m L雾化吸入治疗,每次1吸,每天1次,连续治疗3个月。孟鲁司特组在此基础上加用孟鲁司特钠咀嚼片5 mg,1次/天,睡前口服,连用3个月。采用流式细胞术检测两组患儿治疗前后外周血中CD4+CD25+Foxp3+Treg表达水平,ELISA检测患儿血清中TGF-β1、白介素-10(IL-10)的蛋白表达水平,并进行日、夜间症状评分。结果:两组患儿治疗后日、夜间症状评分均较治疗前显著下降(P<0.05),但孟鲁司特组较常规治疗组下降更为明显(P<0.05);与治疗前相比,治疗3个月后孟鲁司特组和常规治疗组患儿Treg百分率、血清中TGF-β1和IL-10水平均有明显升高(P<0.05),且孟鲁司特组上述指标的升高水平较常规治疗组更显著(P<0.05)。结论:孟鲁司特能有效抑制哮喘的机制,有可能是通过上调哮喘患儿Treg比例,进而分泌表达TGF-β1、IL-10,抑制哮喘中的炎症反应,并显著改善哮喘患儿日、夜间症状评分。
